Brief: TOT Biopharm International Announces Termination Of Phase III Development Of TAA013
17/03/2023 15:09
March 17 (Reuters) - TOT BIOPHARM International Co Ltd
1875.HK :
* TERMINATION OF PHASE III CLINICAL TRIAL STUDY AND
DEVELOPMENT OF
TAA013
Further company coverage: 1875.HK
Recent news on BioDlink International
See all newsCorrected: China's BioDlink International HY revenue falls (September 29)
Brief: Biodlink International To Deliver Ten Batches Of Monoclonal Antibody Intermediates To Wuxi Biologics
Brief: Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares
Brief: HKEX Says Trading In Shares Of Biodlink International Will Be Halted At Dec 29